Optimization of Pellet Coating Techniques
Aparna Raut*1,
PB Suruse3, JG Awari2, AK Raut2 and VV Kale3
1Dr.
Reddys Labs. Ltd., Global Regualatory
Affairts,
2Department
of Pharmaceutical Sciences,
3Sharad
ABSTRACT
In the present study,
pellets were prepared and optimization of pellets coating technique was done.
Extrusion-spheronization technique was employed to
prepare pellets by optimizing operational variables like spheronization
time, spheronization speed and percent of granulating
fluid to obtain smooth and spherical pellets. Pellets were coated employing
spray coating and powder layered coating techniques in order to obtain
sustained release. Hydroxy Propyl
Methyl Cellulose (HPMC) K-15M was used as a coating polymer. Diclofenac sodium
loaded pellets (20%) were prepared with 76% MCC and PVP K-30 at spheronization speed of 120 RPM for 20 min using 76%
granulating fluid. Spray coating was done employing HPMC K-15M solution (1%) in
(70: 30) water: ethanol mixture. Powder layering was done using 5% PVP K-30 in
(50: 50) ethanol: water mixture as binder solution and powdered HPMC K-15M.
Both the processes were continued till 5% coating level was achieved. Powder
layered and spray coated pellets were evaluated for physical characteristics
like drug content and in-vitro drug
release. Physical characteristics like angle of repose, bulk density, tapped
density, friability, moisture content and percentage drug content were found to
be within standard limits. In-vitro
drug release was found to be 0.5 to 1% in pH 1.2 buffer from both the pellets.
In pH 6.8 buffer powder layered pellets showed 25% drug release, while spray
coated pellets showed 45% drug release after 7 h. From the above study, it was
concluded that powder layered pellets sustain drug release more than spray
coated pellets.
KEYWORDS:
Pellets,
Diclofenac sodium, Spray coating, Powdered layer coating, Extrusion-spheronization technique.
INTRODUCTION
Optimization
is usually associated with minor modifications in the basic formula. The
selection of a specific formulation depends on the coating equipment and
conditions available, the intended purpose of coating and the total solid load
desired in the coating (James et al., 1987). Diclofenac sodium, the sodium salt
of [2-(2, 6-dichlorophenyl amino) phenyl] acetic acid, is a well known drug
available in various pharmaceutical dosage forms. It is a potent nonsteroidal anti-inflammatory drug with pronounced
analgesic and antipyretic properties (Oddsson et al.,
1990). It has weak acidic properties (pKa about 4) and its solubility depends on the pH of the
medium. It is slightly soluble in water, very slightly soluble in phosphate
buffer at pH 6.8 and practically insoluble in hydrochloric acid at pH 1.1 (Adeyeye et al., 1990). Pelletization
is an aglomeration process that converts fine powder
or granules of bulk drugs and excipients into small, free flowing, spherical or
spherical units referred to as pellets (Reynolds and Conine
et al., 1970). Generally the particle sizes of pellets are between 0.5 to 1.5
mm depending on the preparation of technique (Ghebre
et al., 1989). Pellets provide a reduction in the dosage regimen and
gastrointestinal irritation moreover controlling the drug release and
increasing the absorption of the active ingredient. Also one of the
advantageous properties of the pellet formulations is being good candidates for
the delivery of the drug substances due to minimizing the dose dumping effect (Palsson et al., 1990).
Figure
1: Calibration curve for Diclofenac sodium
Figure
2: Cumulative % Drug release from 5% powder layered pellets
Figure 3: Cumulative % Drug release from 5%
spray coated pellets
The
reproducibility of the release characteristics (Wu et al., 1998) from pellet
formulations is also much better with respect to the single unit dosage forms (Zhon et al., 2003). They are suitable systems
for film coating with respect to the low surface area-volume ratios (Iyer et al., 1993). Also, resistance to external factors
such as moisture, air and light are the most advantageous properties of this
dosage form (Heng). The objective of present study
was to prepare pellets employing extrusion-spheronization
technique (Dougles and Connor et al., 1989) and to
optimize pellet coating techniques and to compare drug release from spray
coated and powder layered pellets (Heng et al.,
2001).
Figure 4: IR spectra of Diclofenac sodium
Figure 5: IR spectra of HPMC K-15 M
Figure 6: IR spectra of PVP K-30
MATERIALS AND
METHODS:
Materials:
The
active substance Diclofenac sodium is generously obtained from Zim Labs.
Table 1: Preparation of Diclofenac sodium
(20%) loaded pellets
Ingredient |
Quantity (%) |
Diclofenac
sodium |
20 |
MCC |
76 |
PVP |
4 |
Water |
As
required |
Table
2: Processing conditions used to prepare Diclofenac sodium pellets
Spheronization time |
20 min |
Spheronization speed |
120 RPM |
% granulating fluid |
76% |
Table 3: Evaluation of
physical parameters of pellets
Sr.
no. |
Property |
Powder
layered pellets |
Spray
coated pellets |
1 |
Angle of repose |
22.32 |
24.56 |
2 |
Bulk density |
0.8 |
0.84 |
3 |
Tapped density |
0.85 |
0.89 |
4 |
% friability |
0.22 |
0.28 |
5 |
Mean diameter(µm) |
1084 |
1032 |
6 |
Surface area (µm) |
3689675.8 |
3344175.4 |
7 |
% Moisture content |
2.42 |
2.98 |
8 |
% Drug content |
99.24 |
99.10 |
Preparation of
non-drug loaded pellets:
Microcrystalline
cellulose (96%) was weighed and granulated with 4% PVP solution in water and
additional water was added as needed to achieve consistency of the wet mass for
extrusion-spheronization. The wet mass was
immediately passed through extruder and extrudes so obtained was spheronized in the spheronizer (Umprayan et al. 1999). Various batches of above formulation
were prepared keeping ingredients and their quantity constant and varying one
processing variable at a time and keeping others constant.
Preparation of drug loaded pellets:
From the
optimization of processing parameters like spheronization
time, spheronization speed and % of granulating fluid
using non-drug loaded pellets, Diclofenac sodium (20%) loaded pellets were
prepared. Microcrystalline cellulose (76%) and Diclofenac sodium (20%) were
weighed and granulated with 4% PVP solution in water. Additional water was
added as needed to achieve consistency of the wet mass for extrusion-spheronization (Dyer et al., 1995). The wet mass was
immediately passed through extruder and extrudes so obtained was spheronized in the spheronizer
(Table 1).
Coating of drug loaded pellets:
Spray
coating:
HPMC K-15M solution in
water: ethanol (70: 30) mixture was used as coating solution. Preweighed quantity of Diclofenac sodium pellets were
placed in a conventional coating pan and coating was continued till 5% coating
obtained (Heng et al., 1996).
Powder
layering:
5%
binder solution of PVP K-30 was made in ethanol: water mixture. Weighed
quantity of pellets was placed in a spheronizer at
speed of 120 RPM. With the help of syringe drop by drop binder solution was
added on rotating pellets in spheronizer followed by
addition of powdered HPMC K-15M and the process was continued till 5% coating
level was achieved (Oshlack et al.,).
Figure 7: IR spectra of pellet
Figure 8: IR spectra of MCC
Evaluation of pellets:
Characterization
of pellets:
Pellets
were characterized for parameters like friability (Sinha
et al., 2005), angle of repose (Bankere et al.,
1991), size distribution, bulk density, tapped density, moisture content,
particle size and surface area (Martin et al., 1991). Particle size analysis
and surface area determination was carried out by Motic
Microscopy and results are shown in Table 3.
Construction of calibration curve for
Diclofenac sodium:
A series of
Diclofenac sodium concentration ranging from 5-50 µg/ml was made from
standard
solution in pH 6.8 phosphate buffer. Absorbance was measured at 276 nm and
standard
curve was made by plotting absorbance versus concentration of the drug.
Determination
of drug content:
Crushed sample from
each formulation equivalent to 100 mg drug was weighed and transferred to 100
ml volumetric flask and diluted to 100 ml with phosphate buffer and filtered. 1
ml solution was taken and diluted to 100 ml with pH 6.8 phosphate buffer and
absorbance was measured at 276 nm and by using calibration curve of Diclofenac
sodium drug content was determined.
In-vitro drug release:
In-vitro
dissolution of drug loaded spray coated and powder layered pellets was carried
out using USP Dissolution Apparatus 1(basket type). The dissolution test was
performed using 900 ml of dissolution medium at 37± 0.5°C at 50 RPM.
Dissolution medium used was pH 1.2 buffer for first 2 h and pH 6.8 buffer for
next 5 h. Absorbance of these solutions was measured at 276 nm (Woodruff et
al., 1972).
Stability studies:
Stability
studies of pellets were carried out at 75% RH at 40°C for 45 days. Interaction of drug and excipients was
studied by using UV and IR spectroscopy (Heng et al.,
2000).
RESULT
AND DISCUSSION:
From
optimization of processing variables for shape of pellets, it was observed that
spherical pellets were formed from the base formula for non drug loaded pellets
at spheronization speed of 1000 RPM, spheronization time of 15 minutes and 96% of granulating
fluid. The processing conditions used to prepare Diclofenac sodium pellets and
the results of evaluation for physical parameters of both spray coated and
powder layered pellets are shown in Table 1 and Table 2 respectively. Calibration curve for Diclofenac sodium are
drawn by using pH 6.8 phosphate buffer at 276 nm (Figure 1). In vitro
dissolution of pellets showed that powder layered pellets release 35% of drug
in pH 6.8 buffer and spray coated pellets release 45% of drug in pH 6.8 buffer
(Figure 2 and Figure 3). Stability studies revealed that the formulation
developed was found to be stable under short-term stability studies. UV and IR
spectroscopy showed no chemical interaction between drug and excipients.
CONCLUSION:
Both
the formulation spray coated and powder layered pellet were evaluated for physical
properties like angle of repose, bulk and tapped density, % friability, mean
diameter (µm), surface area (µm), %moisture content and % drug content. From
the evaluation of both coated pellets formulation posses good physical
properties within specified ranges. The dissolution of optimized formulation
batch was carried out in type-1 USP dissolution apparatus. The dissolution was
carried out in pH 1.2 buffer for first 2 h and continued in pH 6.8
buffer. The results revealed that 5% spray coated pellet release 45% drug after
7 h in pH 6.8 buffer while 5% powder
layered pellet release only 35% drug. Thus, it can be concluded that powder
layered pellets sustain drug release more than spray coated pellets. Stability
study for the optimized formulation batch was performed for 45 days at 75% RH
at 40°C. The drug content was determined by assay method. There was
no significant change in the drug content when analyzed significantly. Thus
stability study revealed that the combination formulation developed found to be
stable under short term stability studies.
ACKNOWLEDGEMENT:
Authors
are thankful to the HOD, Department of Pharmaceutical Sciences, RTM
REFERENCES:
1.
James AS, Mehta SP and James LY. Tablet
coating. In Lachman and Liberman’s
(eds.), The Theory and Practice of Industrial Pharmacy, Varghese Publication
House,
2.
Oddsson E, Gudjonsson H and Scand J. Gastroenterol.
25: 231-234 (1990).
3.
Adeyeye CM and Li
PK. In Florey K (eds.), Analytical Profiles of Drug Substances, Academic Press,
4.
Reynolds AD. A new technique for the
preparation of spherical particles. Manu. Chem. Aerosol. News. 1: 40-43 (1970).
5.
Conine JW and Hadely HR. Preparation of small solid pharmaceutical
spheres. Drug. Cosmet.
6.
Ghebre SI.
Pellets: A general overview. In Ghebre-Sellassie
(eds.), Pharmaceutical Pelletization Technology,
Marcel Dekker Inc.
7.
Palsson BO,
Wheatley TA and Dressman JB. Mechanism of release
from pellets coated with an ethycellulose based film.
J. Cont. Release. 14: 203-213 (1990).
8.
Wu XY, Eshun G and
Zhou Y. Effect of interparticulate interaction on
release kinetics of microsphere ensemles. J. Pharm.
Sci. 87: 586-593 (1998).
9.
Zhon Y and Wu
XY. Modeling and analysis of dispersed drug release into a finite medium from
sphere ensembles with a bondary layer. J. Control.
Release. 90: 23-36 (2003).
10.
Iyer RM, Augsburger LL and Parikh DM. Evaluation of drug layering
and coating: Effect of process mode and binder level. Drug.
11.
Heng PWS, Wan
LSC and Tan YTF. Relationship between aggregation of HPMC coated spheroids and
tackiness/viscosity/additives of the coating formulations. Int. J. Pharm. 138:
57-66 (1996).
12.
Dougles CH and
Howard LF. In Ghebre-Sellassie (eds.), Pharmaceutical
Technology. Marcel Dekker Inc.
13.
Connor RE and Schwartz JB. In Ghebre-Sellassie (eds.), Pharmaceutical Technology. Marcel
Dekker Inc.
14.
Heng PWS and
Koo OMY. A study of the effects of physical properties of microcrystalline
cellulose on performannce in extrusion speronozation. Pharm. Research. 18(4): 480-487 (2001).
15.
Umprayan K, Chitropas P, and Amarekajorn S.
Influence of process variable on physical properties of pellets using Extruder
and Spheronizer. Drug.
16.
Dyer AM, Khan KA, and Aulton
ME. Effect of polymer loading on drug release from film-coated ibuprofen
pellets prepared by extrusion-spheronization. Drug.
17.
Oshlack B, Pedi JR
and Frank. Powder-layered morphine sulphate
formulations. United State Patent.
18.
Sinha VR and Agrawal MK. Influence of formulation and excipient variables on the pellet properties prepared by
extrusion-speronozation. 2: 1-8 (2005).
19.
Banker GS and Anderson NR. In Lachman and Liberman (eds.), The
theory and practice of Industrial Pharmacy. Lea and Febiger,
Philadelpia, 1991, pp. 293-295.
20.
Martin A and Swarbrick
AC. Physical Pharmacy. KM Verghese Company, Mumbai
1991.
21.
Woodruff CW and Nuessle
NU. Effect of processing variables on particle obtained by extrusion spheronization. J. Pharm. Sci. 61: 787-790 (1972).
22.
Heng PWS, Wang
TW and Chan LW. Influence of production variables on the sphericity
of melt pellets. Chem. Pharma Bull. 48(3): 420-424 (2000).
Received on
16.04.2009
Accepted on
12.06.2009
© A&V
Publication all right reserved
Research
Journal of Pharmaceutical Dosage Forms and Technology. 1(3): Nov. – Dec. 2009, 184-187